Sharman Showcases Frontline Acalabrutinib Activity in CLL

Jeff P. Sharman, MD, discusses updated data from the ELEVATE-TN trial and ongoing research that is poised to define the optimal role of acalabrutinib in chronic lymphocytic leukemia.

Read the full article here

Related Articles